Creating long-lasting immune cells to fight Epstein-Barr Virus
Developing Monoclonal Antibody Secreting Human Plasma Cells to Provide Long-Lasting EBV Immunity in Humanized Mice
This study is testing a new treatment that uses specially modified cells to create long-lasting protection against the Epstein-Barr Virus with just one dose, making it easier and more affordable for patients to stay healthy.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11046501 on NIH RePORTER |
What this research studies
This research focuses on developing a new type of treatment that uses engineered human plasma cells to produce monoclonal antibodies (mAbs) against the Epstein-Barr Virus (EBV). By utilizing advanced gene editing techniques, the goal is to create plasma cells that can provide lifelong immunity with a single administration, eliminating the need for repeated infusions. The study will assess the effectiveness of these engineered cells in producing the necessary antibodies and their potential for future therapies. This innovative approach aims to improve patient adherence and reduce treatment costs.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals at risk for or affected by Epstein-Barr Virus infections.
Not a fit: Patients who are not affected by Epstein-Barr Virus or do not have related health conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide patients with a long-lasting and cost-effective treatment option for EBV-related conditions.
How similar studies have performed: While the approach of using engineered plasma cells is relatively novel, there have been successful applications of monoclonal antibody therapies in other contexts.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Hill, Tyler F — University of Washington
- Study coordinator: Hill, Tyler F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.